Ready for the Talk
"Diet, exercise, oral medications, and I’m still not controlled."
- Ready for the Talk

About 80% of patients on OADs would consider starting insulin based on their physician's advice1,a

You may want to have the insulin talk sooner

More patients may be receptive to insulin than you think.

Rethinkinsulin.com View Patient Discussion Guide

It's never too early to have a discussion about insulin with patients. Over time, diabetes treatment plans may need to be adjusted as the disease progresses. While this may pose a challenge to physicians, it may be frustrating for patients as well. Patients may not be aware that their pancreas is no longer making enough insulin and that their disease has progressed.2

Your recommendation of adding insulin as part of overall approach to controlling blood glucose may help move a patient towards acceptance.

  • A physician recommendation may increase the willingness of a patient to consider taking insulin1
  • About 80% of patients on OADs would consider starting insulin based on their physician's advice1,a
Next >

Important Safety Information for Lantus®

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and precautions

Monitor blood glucose in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Do not dilute or mix Lantus® with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus® via an insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices and needles must not be shared between patients.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®, and may be life-threatening.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur.

A reduction in the Lantus® dose may be required in patients with renal or hepatic impairment.

Drug interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

Adverse reactions

Other adverse reactions commonly associated with Lantus® are injection site reaction, lipodystrophy, pruritus, and rash.

Important Safety Information for Lantus® SoloSTAR®

Lantus® SoloSTAR® is a disposable prefilled insulin pen. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose.

Indications and Usage for Lantus®

Lantus® is a long-acting insulin analog indicated to improve glycemic control in adults and children (6 years and older) with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus® should be administered once a day at the same time every day.

Important Limitations of Use: Lantus® is not recommended for the treatment of diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Please click here for full prescribing information

a.Survey of patients with T2DM uncontrolled on oral medications.

References: 1. Data on file, sanofi-aventis, 2009.
2. Polonsky WH, Jackson RA. Clin Diabetes. 2004;22(3):147-150.